Why the study?
Cathepsins may play a crucial role in cardiomyopathies, but studies establishing causality were lacking.
Do genetically predicted levels of cathepsins affect the risk of developing cardiomyopathies?
Population
Pooled data from genome-wide association studies of cardiomyopathies
Comparison
Genetically predicted levels of 9 cathepsins
Design
Mendelian randomization study
Key result
Genetically predicted elevated levels of cathepsin E were associated with an increased risk of overall cardiomyopathy (OR 1.078; 95% CI 1.002-1.160; P=0.045).
Authors
Loading...
No immediate clinical implications for cardiomyopathy risk stratification; leaves open cathepsin E as a potential target pending replication.
Observational
Do genetically predicted levels of cathepsins affect the risk of developing cardiomyopathies?
Effect estimate: OR 1.078 (95% CI 1.002-1.160)
p-value: p=.045
This Mendelian randomization study provides genetic evidence for a causal relationship between specific cathepsins (E, B, L2, O) and the development of cardiomyopathies, highlighting potential novel therapeutic targets.
Chen et al. (2024) conducted an observational in Cardiomyopathy. Genetically predicted cathepsin levels was evaluated on Overall cardiomyopathy (OR 1.078, 95% CI 1.002-1.160, p=.045). Genetically predicted elevated levels of cathepsin E were associated with an increased risk of overall cardiomyopathy (OR 1.078; 95% CI 1.002-1.160; P=0.045).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: